Business Wire

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Share

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP. The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for rADAMTS13 throughout the European Union (EU). If approved, rADAMTS13 will be the first and only enzyme replacement therapy in the EU for the treatment of cTTP.3

“People living with cTTP experience serious, potentially fatal health challenges and have limited treatment options in the European Union,” said Obi Umeh, M.D., M.Sc., Vice President, Franchise Global Program Leader at Takeda. “With this positive opinion for recombinant ADAMTS13, we are one step closer to offering patients in the EU the first treatment specifically indicated for cTTP. We look forward to the European Commission’s decision as we aspire to transform the standard of care for cTTP for more patients around the world.”

cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.1 It is associated with acute events and debilitating chronic symptoms or thrombotic thrombocytopenic purpura (TTP) manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, renal manifestations, stroke and abdominal pain.1,2,4 Untreated, acute TTP events have a mortality rate of >90%.1,2

The Committee’s positive opinion was supported by the totality of evidence including the interim analysis of efficacy, pharmacokinetic, safety and tolerability data from the first randomized, controlled open-label, crossover Phase 3 trial in cTTP. Data from this trial (NCT03393975) were published in TheNew England Journal of Medicine in May 2024. rADAMTS13 is also being investigated in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), the acquired form of TTP, in an ongoing Phase 2b trial (NCT05714969).

About Recombinant ADAMTS13 (rADAMTS13)
rADAMTS13 is the first and only recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (ADAMTS13) enzyme replacement therapy developed for the treatment of cTTP. Marketed in the U.S. and Japan as ADZYNMA, rADAMTS13 was approved by the U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labour and Welfare (MHLW) for the prophylactic and on-demand treatment of patients with cTTP.

rADAMTS13 was granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment and prevention of TTP, including its acquired idiopathic and secondary forms, as well as Fast Track and Rare Pediatric Disease Designation. The U.S. FDA granted Takeda a Rare Pediatric Disease Voucher for the approval of rADAMTS13. rADAMTS13 was also previously granted ODD by the European Medicines Agency (EMA) and Japanese MHLW for the treatment of TTP.

About cTTP
cTTP is an ultra-rare, chronic and debilitating clotting disorder associated with life-threatening acute events and debilitating chronic symptoms, or TTP manifestations.5,6 TTP has an estimated prevalence of 2-6 diagnosed cases/million. The inherited form of the disease, cTTP, accounts for ≤5% of TTP patients.6,7,8 It develops due to deficiency in ADAMTS13, a von Willebrand factor (VWF) cleaving protease, which results in the accumulation of ultra-large VWF multimers in the blood.5 The accumulation of ultra-large VWF multimers leads to uncontrolled platelet aggregation and adhesion.4,6 This can lead to abnormal clotting in the small blood vessels of the body and is associated with microangiopathic hemolytic anemia and low platelet levels (thrombocytopenia).4

cTTP has both acute and chronic manifestations (including stroke, renal and cardiovascular disease). cTTP can also cause ongoing widespread organ damage and other co-morbidities resulting from an ADAMTS13-deficient state.2,6,9,10

About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References:

  1. Van Dorland H et al. Haematologica. 2019;104:2107-16
  2. Joly BS et al. Blood. 2017;129(21):2836–2846
  3. Scully M et al. Blood. 2017; 130:2055-63
  4. Chiasakul T and Cuker A. Am Soc Hematol. 2018;2018(1):530–538
  5. Alwan F et al. Blood. 2019;133:1644-51
  6. Kremer Hovinga JA et al. Nat Rev Dis Primers. 2017;3:17020
  7. Kremer Hovinga JA and George JN. Hereditary Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;381(17):1653-1662
  8. Orpha.net. Congenital thrombotic thrombocytopenic purpura. https://www.orpha.net/en/disease/detail/93583. Accessed May 2024
  9. Zheng XL et al. J Thromb Haemost. 2020;18(10):2486-95
  10. Sukumar S et al. J Clin Med. 2021;10:536

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Japanese Media
Jun Saito
jun.saito@takeda.com

U.S. and International Media
Mark Dole
mark.dole@takeda.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verimatrix To Showcase Mobile App Protection Platform at OWASP Events in Lisbon and San Francisco24.6.2024 18:45:00 EEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced its participation in two leading events organized by the Open Worldwide Application Security Project (OWASP). The following conferences will showcase the award-winning Verimatrix Extended Threat Defense (XTD) mobile app security solutions: OWASP Global AppSec Lisbon 2024 – June 24-28, 2024 Lisbon Congress Centre – Lisbon, Portugal https://lisbon.globalappsec.org/ OWASP Global AppSec San Francisco 2024 – September 23-27, 2024 Hyatt Regency San Francisco – San Francisco, California https://sf.globalappsec.org/ Bringing together those tasked with ensuring proper security for apps, the associated enterprise, as well as their app users, OWASP events serve as leading venues to illustrate the value and differentiation that comes with proactively deploying mobile app protections. Verimatrix XTD mobile app security solutions quickly a

Armis Named ‘Outperformer’ and ‘Leader’ in GigaOm Radar Report for Operational Technology Security for Second Consecutive Year24.6.2024 18:15:00 EEST | Press release

Armis, the asset intelligence cybersecurity company, today announced that it has been named a Leader and Outperformer in the 2024 GigaOm Radar Report for Operational Technology (OT) Security. This is the second year running is recognized as a Leader in the field of OT Security, cementing its status as a mature platform solution providing proactive end-to-end security for cross-vertical organizations looking for a cohesive approach to OT Security management. Armis scored multiple 5/5 perfect scores showcasing Armis’ customer-centric vision to deliver OT security built on deep asset context, proactive threat intelligence and total vulnerability management. From cost and ease of use to scalability and flexibility and certification, Armis was recognized for being built for smooth deployment in OT environments. “The on-going development of the Armis Centrix™ platform has enabled us to offer complete end to end OT security management from complete visibility, vulnerability remediation and ma

H.I.G. Capital Raises $1.3 Billion for Infrastructure Fund24.6.2024 16:30:00 EEST | Press release

H.I.G. Capital (“H.I.G.” or “the Firm”), a leading global alternative asset management firm with $64 billion of capital under management, is pleased to announce the closing of H.I.G. Infrastructure Partners (the “Fund”). The Fund closed with aggregate capital commitments of approximately $1.3 billion.1 H.I.G. Infrastructure Partners seeks to make control-oriented, infrastructure equity investments focused on the middle market segment, leveraging H.I.G.’s focus on the middle market and its operational value creation expertise. To date, across North America and Europe, the Fund has made seven investments, two of which are expected to close in Q3 2024. Sami Mnaymneh and Tony Tamer, Co-Founders of H.I.G., commented, “We greatly appreciate the strong support from our investors for our Infrastructure strategy. Their confidence in our investment approach to infrastructure underscores the power of the Firm’s platform and our ability to generate strong returns through value creation in the unde

Grid Dynamics Releases a GenAI Toolkit to Enhance Developer Productivity24.6.2024 16:15:00 EEST | Press release

Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and advanced analytics services, unveils its AI for Developer Productivity Toolkit. This toolkit provides specialized applications for common software development scenarios including application modernization, functional test automation, and cloud deployment observability. These purpose-built tools enable development teams to solve corresponding problems faster and more efficiently than general-purpose coding LLMs and copilots. This release includes three new tools to address three in-demand use cases across Grid Dynamics’ client base. The first tool, AI Application Modernization, performs architectural analysis of legacy applications, generates detailed specifications for the target technology stack, and implements these specifications in the code. The second tool, AI Test Automation, enables end-to-end functional test generation by analyzing

Adtran and Iridium strengthen PNT resilience in Europe and Asia-Pacific with Satellite Time and Location technology24.6.2024 15:00:00 EEST | Press release

Adtran, in partnership with Iridium Communications Inc. (NASDAQ: IRDM), today announced the European and Asia-Pacific launch of its synchronization solutions featuring Iridium® Satellite Time and Location (STL) technology, a significant step in countering growing threats to Global Navigation Satellite Systems (GNSS). Adtran’s OSA 5405-S PTP compact grandmaster clock with STL capabilities and its OSA 5400 STL module are now available to timing network operators in Western Europe, major countries in Eastern Europe, Turkey, and parts of Asia-Pacific, including the majority of Southeast Asia, Japan and South Korea. The solutions enhance the resilience and reliability of critical infrastructure, such as 5G networks, defense systems and many more. Leveraging low-Earth orbit (LEO) satellites to deliver precise and secure positioning, navigation and timing (PNT) services, the devices ensure continuous synchronization even in environments where GNSS is compromised. As a certified Iridium partne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye